6667 (6667) Fair Value & Analysis

Healthcare · Market cap HK$1.6B

6 6667 6667 · HK

PriceHK$7.11

Fair ValueHK$2.98

Upside-58.1%

Quality62/100

Watch 6667 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$2.24 – HK$3.73

Fair value as of: Jul 2, 2026

From 15 valuation models · updated today

Share price +0.9% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$6.54 – HK$7.21 · fair‑value band HK$2.24 – HK$3.73 · the HK$7.11 price screens above the HK$2.98 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

6667 (6667) currently trades at HK$7.11, while our model-based Fair Value estimate is HK$2.98 — implying the stock looks roughly 58.1% overvalued today. We read business quality at 62/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, 6667 generated revenue of HK$247M at a net margin of 10.9%. Revenue grew 191.3% year over year. It earns a return on equity of 4.4%. The balance sheet holds a net cash position of HK$386M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$247M

Revenue growth (YoY) +191%

Net margin 10.9%

Return on equity 4.4%

Free cash flow −HK$16.7M FY2025

P/E ratio 44.4

More key figures

Operating margin -1.7%

Dividend yield 2.1%

EPS growth (YoY) -26.3%

Net cash HK$386M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

6667 reported revenue of HK$247M in FY2025 versus HK$237M in FY2021, a compound +1.0%/yr. Reported net income was HK$26.3M in FY2025, compounding −24.0%/yr from FY2021.

Revenue +1.0%/yr

FY21 HK$237M

FY22 HK$146M

FY23 HK$151M

FY24 HK$164M

FY25 HK$247M

Net income −24.0%/yr

FY21 HK$79.0M

FY22 −HK$17.6M

FY23 HK$30.0M

FY24 HK$45.0M

FY25 HK$26.3M

Is 6667 fairly valued? → Check now

Similar stocks

6 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
Thermo Fisher Scientific Inc TMO	$464.01	$326.81	-30%
Danaher Corporation DHR	$183.63	$87.65	-52%
2359 2359	HK$152.80	HK$120.99	-21%
WuXi AppTec Co WUXAY	$18.59	$25.09	+35%
IDEXX Laboratories, Inc IDXX	$562.16	$190.95	-66%
Lonza Group LZAGY	$61.97	$14.23	-77%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 6667 (6667) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$2.98 versus a price of HK$7.11 — about −58% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 6667?

Our model-based fair value for 6667 is HK$2.98 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$7.11.

What is the quality score of 6667?

6667 has a Quality Score of 62/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 6667 (6667)?

6667 reported trailing-twelve-month revenue of about HK$247M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 6667?

The net profit margin of 6667 is about 10.9%, meaning it keeps roughly 10.9% of revenue as net income. Based on the latest reported figures.

Does 6667 pay a dividend?

6667 currently shows a dividend yield of about 2.11% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.